SB140
To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.
Last Action (Jan. 29, 2025): Sine Die adjournment
Sponsors
AI-Generated Summary
Senate Bill 140 creates a framework to increase the usage and accessibility of biosimilar and generic medicines within private and nonfederal governmental health benefit plans in Arkansas. It requires health benefit plans to maintain and publish easily accessible, up-to-date formularies that clearly detail coverage tiers and drug restrictions. When a generic or biosimilar medication is marketed at a lower wholesale acquisition cost than its reference drug or biological product, the bill mandates that the health plan provide more favorable cost-sharing for the lower-cost option. Furthermore, it prohibits health plans from imposing prior authorizations, step therapy requirements, or discriminatory access restrictions on these lower-cost alternatives, provided they remain cheaper than the reference product. The legislation also establishes that plans are not required to continue covering older brand drugs or products if they are deemed no longer medically appropriate or cost-effective. Finally, the bill grants the Insurance Commissioner and the State Board of Finance the authority to promulgate rules for implementation, with an effective date of January 1, 2026.
Potential Impact Analysis
Who Might Benefit?
The primary beneficiaries include patients covered by private or state-sponsored health benefit plans who rely on prescription medications, as the bill aims to lower out-of-pocket costs and improve access to biosimilar and generic alternatives. Additionally, the public and healthcare providers benefit from increased transparency in insurance formularies, which helps in making more informed decisions regarding medication choices and treatment planning.
Who Might Suffer?
Pharmaceutical companies that manufacture reference brand-name drugs and original biological products may be negatively impacted, as the bill incentivizes patients and insurers to shift toward lower-cost generic and biosimilar competitors. Additionally, healthcare insurers and pharmacy benefit managers may face increased administrative burdens and potential revenue shifts as they are required to update formularies, remove prior authorization barriers, and adjust their coverage structures to comply with the new mandates.
Get Notified
Receive an email when this bill's status changes.